Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 9/20 | 0.61 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.31 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572905 | 0.95 | ALOX5 (0.60) | ALOX5PIK3CDALDH1A1 | |
| SCHEMBL3567948 | 0.93 | ALOX5 (0.61) | ALOX5PIK3CDROCK2AVPR1B | |
| SCHEMBL3566842 | 0.93 | ALOX5 (0.63) | ALOX5DHODHPIK3CDROCK2AVPR1B | |
| SCHEMBL3574400 | 0.93 | ALOX5 (0.61) | ALOX5PIK3CDROCK2AVPR1B | |
| SCHEMBL3566023 | 0.92 | ALOX5 (0.60) | ALOX5CTSKAVPR1BALDH1A1 | |
| SCHEMBL3576330 | 0.89 | ALOX5 (0.61) | ALOX5PIK3CDROCK2AVPR1BALDH1A1 | |
| SCHEMBL3571273 | 0.89 | ALOX5 (0.60) | ALOX5PIK3CDROCK2AVPR1BALDH1A1 | |
| SCHEMBL3572355 | 0.87 | ALOX5 (0.58) | ALOX5DHODHPIK3CDROCK2ALDH1A1 | |
| SCHEMBL3573625 | 0.85 | ALOX5 (0.63) | ALOX5DHODHPIK3CDROCK2AVPR1B | |
| SCHEMBL3567787 | 0.85 | ALOX5 (0.42) | ALOX5CTSKPIK3CDROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674811-B2 | 5-lipoxygenase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-09 | — | — | US | claimed |
| US-20080021080-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-01-24 | — | — | US | claimed |
| EP-1834953-A1 | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors | Ranbaxy Laboratories Limited (IN) | 2007-09-19 | — | — | EP | claimed |
| US-7674811-B2 | 5-lipoxygenase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-09 | — | — | US | disclosed |
| US-20080021080-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-01-24 | — | — | US | disclosed |
| EP-1834953-A1 | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors | Ranbaxy Laboratories Limited (IN) | 2007-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021080-A1 | 5-LIPOXYGENASE INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5 1/4885DHODH 400/4885CTSK 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.